MEA Diabetes Market Size

Middle East and Africa Diabetes Market Overview

Middle East and Africa Diabetes Market Size was valued at USD 1.17 Billion in 2023. The Middle East and Africa Diabetes market industry is projected to grow from USD 1.25 Billion in 2024 to USD 2.005 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.08% during the forecast period (2024 - 2032). Increased count of diabetic patients due to changing lifestyles and unhealthy & junk food consumption are the key market drivers enhancing market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Middle East and Africa Diabetes Market Trends

• Changing lifestyles is driving the market growth

Market CAGR for Middle East and Africa diabetes market is being grown due to continuous changing lifestyles. The prevalence of diabetes has alarmingly increased in recent years throughout the Middle East and Africa. Diabetes rates are at an all-time high, mostly as a result of lifestyle modifications. The primary motive of diabetes treatment is to keep blood glucose levels in a proper range in order to avoid both immediate and long-term problems such as heart disease, kidney disease, blindness, and lower limb amputation. IDF 2021 reported that 73 million adults in the MENA region have diabetes. 95 million people are anticipated to be added to this number by 2030. Impaired glucose tolerance affects 48 million adults in the IDF MENA Region, putting them at higher risk of type 2 diabetes.

Furthermore, In July 2022, The sale of tablets containing metformin hydrochloride and empagliflozin in a variety of strengths has been officially approved, according to a statement from Zydus Lifesciences. To enhance glycemic control in persons with type-2 diabetes mellitus, empagliflozin and metformin hydrochloride tablets are used in accordance with a healthy diet and exercise.

Governments in the Middle East have recognized the threat that diabetes poses and have begun to take action with a number of policies, projects, and programs. National guidelines for the treatment of diabetes have been adopted in the majority of nations. In this region, there are still six of the fifteen nations without a national operational action plan for diabetes. Nevertheless, ongoing efforts are made to reduce diabetic complications. It is predicted that the market will expand in the future because of the rising prevalence of type-2 diabetes, the rising prevalence of obesity, and the growing hereditary risk factors for the disease. Thus, driving the Middle East and Africa Diabetes market revenue.

Middle East and Africa Diabetes Market Segment Insights

Middle East and Africa Diabetes Type Insights

The Middle East and Africa Diabetes market segmentation, based on the type include type 1, type 2, and gestational diabetes. Over the projection period, the segment for type 2 is anticipated to increase at the quickest rate. Worldwide, type 2 diabetes is a major and pervasive public health issue. The Middle East and North Africa area has the highest prevalence of diabetes in 2019 (12.2%), along with the accompanying morbidity and mortality. Evidence suggests that obesity, physical inactivity, urbanization, and poor nutritional practices, in addition to a genetic predisposition in its population, have contributed to the high spread of diabetes and prediabetes in the area.

Middle East and Africa Diabetes Test Insights

The Middle East and Africa Diabetes market segmentation, based on test, includes, Random blood sugar test, fasting blood sugar test, oral glucose tolerance test, initial glucose challenge test, and others. The fasting blood sugar test category had the biggest revenue share and is anticipated to hold onto the top position during the anticipated period. Following an overnight fast (without eating), the blood sugar of the patients is measured. Fasting blood sugar levels of 99 mg/dL or less are considered normal, 100 to 125 mg/dL denotes prediabetes, and 126 mg/dL or more denotes diabetes.

Middle East and Africa Diabetes Device Insights

The Middle East and Africa Diabetes market segmentation, based on devices, includes, blood glucose monitoring devices, diabetes management devices, and others. The blood glucose monitoring device category had the biggest revenue share and is anticipated to remain to dominate for the duration of the forecast. On important thing a person can do is treat type 1 or type 2 diabetes is to regularly monitor their blood sugar levels. They will be able to observe what causes their numbers to increase or decrease, such as consuming certain foods, taking medication, or engaging in physical activity. With this knowledge, they may decide on the optimum diabetes management strategy in collaboration with their medical team.

Middle East and Africa Diabetes Treatment Insights

The Middle East and Africa Diabetes market segmentation, based on treatment, includes, medications, insulin therapy, transplantation, bariatric surgery, and others. The insulin therapy category had the biggest share in the revenue and is anticipated to continue dominating the market. Insulin therapy is essential for replenishing the insulin your body doesn't make if you have type 1 diabetes. When alternative therapies fail to keep blood glucose levels within the recommended range, persons with type 2 diabetes or gestational may occasionally need insulin therapy.

Figure 1 Middle East and Africa Diabetes Market, by Treatment, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Middle East and Africa Diabetes Regional Insights

By region, the study provides the market insights into Middle East and Africa. The Middle East and Africa Diabetes market area will dominate this market, owing to an increase in the genetic factors for type 2 diabetics patients. In addition, the growing awareness of the government will boost market growth in this region. The South Africa held the fastest growth while Latin American is anticipated to register the fastest CAGR over the projected period.

Figure 2 MIDDLE EAST AND AFRICA DIABETES MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

In South Africa, one in nine persons have diabetes, according to the IDF Diabetes Atlas 2021. Numerous health issues are related to diabetes. Diabetes patients must make several adjustments throughout the day to keep their blood glucose levels within acceptable ranges. For example, they may need to take additional insulin or consume more carbohydrates. To overcome both instant and long-term problems like cardiovascular disease, kidney disease, blindness, and lower limb amputation, diabetes treatment seeks to maintain optimum blood glucose levels. As a result of the aforementioned factors, it is predicted that the South Africa Diabetes Market would expand during the course of the analysis.

The GCC diabetes market is expanding due to growing number of diabetic pateints in the region. Latin American nations have a high rate of diabetes prevalence. According to the International Diabetes Federation, throughout the past ten years, the percentage of persons in the GCC states who have diabetes has remained largely stable 18.7% in Saudi Arabia, 16.4% in the United Arab Emirates, and 19.5% in Qatar. Comparatively speaking, just 10.7% of Americans have diabetes.

Further, the major countries studied in the market report are South Africa, GCC, and Rest of MEA.

Middle East and Africa Diabetes Key Market Players & Competitive Insights

Leading market players are adopting various strategies to ensure product innovation and development, which will aid the Middle East and Africa Diabetes market, grow faster than ever. Market players are also undertaking a range of business strategies to grow their  footprint, with important market developments including new product developments, contracts & agreements, mergers & acquisitions, increased investments, & collaboration with other similar organizations. To expand and survive in a more competitive and rising market climate, Middle East and Africa Diabetes industry must offer cost-effective items.

Manufacturing locally to minimize capital requirements is one of the key business tactics used by manufacturers in the Middle East and Africa Diabetes industry to benefit clients and increase the market sector. In recent years, the Middle East and Africa Diabetes industry has offered some of the most significant advantages to medicine. Major players in the Middle East and Africa Diabetes market, including Abbott, Bayer AG, Becton Dickinson and Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Roche Diabetes Care, Inc., Sanofi Avnetis U.S. LLC., Ypsomed, and others, are attempting to enhance market demand by investing in research and development operations.

Novartis AG (Novartis) is a healthcare firm which holds expertise in the development, and manufacture of prescription as well as over-the-counter medicines, along with products for eye care. In addition to others, it offers medicines for the treatment of solid tumors, immunological disorders, infections, cardiovascular illness, dermatological issues, neurological disorders, ophthalmic and respiratory diseases, cancer, and neurological disorders. Through Sandoz, the business provides biosimilars and generic medications. In March 2022, According to Novartis, Beovu® (brolucizumab) 6 mg has been authorised by the European Commission (EC) for the treatment of diabetic macular edoema (DME), which causes vision loss. Beovu was first approved by the EC in 20203 for the treatment of wet age-related macular degeneration; this approval in DME is its second indication.

A wide variety of healthcare goods are discovered, developed, produced, and sold by Abbott Laboratories (Abbott), including branded generic medications, diagnostic tools and procedures, and infant, child, and adult nutritional supplements. The business also sells a range of medical devices, such as those for neuromodulation, electrophysiology, rhythm control, vascular and structural cardiac devices, and heart failure. The business also sells dietary supplements, minerals, and nutrition goods. In February 2022, To usher in a new era of comprehensive diabetes management care, Abbott announced new partnerships with important health-tech companies BeatO, Healthifyme, Pharmeasy, Sugar.fit, and Fitterfly.

Key Companies in the Middle East and Africa Diabetes market include

• Abbott


• Bayer AG


• Becton Dickinson and Company


• Johnson & Johnson Services, Inc.


• Merck & Co., Inc.


• Novartis AG


• Novo Nordisk A/S


• Roche Diabetes Care, Inc.


• Sanofi Avnetis U.S. LLC.


• Ypsomed

Middle East and Africa Diabetes Industry Developments

July 2022: Novo Nordisk introduced the first-ever oral GLP-1 RA medication to help people with type-2 diabetes manage their blood sugar. It has been approved by the Saudi Food and Drug Authority and is currently in use throughout the Arab globe.

Middle East and Africa Diabetes Market Segmentation

Middle East and Africa Diabetes Type Outlook

• Type 1


• Type 2


• Gestational Diabetes,

Middle East and Africa Diabetes Test Outlook

• Random blood sugar test


• Fasting blood sugar test


• Oral glucose tolerance test


• Initial glucose challenge test,


• Others,

Middle East and Africa Diabetes Device Outlook

• Blood glucose monitoring devices


• Diabetes management devices


• Others,

Middle East and Africa Diabetes Treatment Outlook

• Medications


• Insulin Therapy


• Transplantation


• Bariatric Surgery


• Others

Middle East and Africa Diabetes Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America